Clinical Trial

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

Study acronym: TroFuse-021
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance treatment, which is used after another therapy to keep the cancer from growing, spreading, or coming back. Bevacizumab is a targeted therapy used as standard maintenance treatment. Targeted therapy works to control how specific types of cancer cells grow and spread. * Observation, which is watching to see if cancer grows or worsens The study medicine, sacituzumab tirumotecan (also called sac-TMT), is a targeted therapy. The goal of this study is to learn if people who receive sac-TMT maintenance treatment with or without bevacizumab live longer without the cancer getting worse than people who receive standard care.
Protocol Amendment History 18 changes
notable Trial sites expanded: 144 -> 151 locations 2026-08-15
notable Trial sites expanded: 138 -> 144 locations 2026-08-08
notable Trial sites expanded: 135 -> 138 locations 2026-08-04
notable Trial sites expanded: 125 -> 135 locations 2026-07-28
notable Trial sites expanded: 118 -> 125 locations 2026-07-21
notable Trial sites expanded: 115 -> 118 locations 2026-07-07
notable Trial sites expanded: 108 -> 115 locations 2026-06-30
notable Trial sites expanded: 99 -> 108 locations 2026-06-23
notable Trial sites expanded: 89 -> 99 locations 2026-06-13
notable Trial sites expanded: 77 -> 89 locations 2026-06-09
notable Trial sites expanded: 60 -> 77 locations 2026-05-30
notable Trial sites expanded: 50 -> 60 locations 2026-05-23
notable Trial sites expanded: 41 -> 50 locations 2026-05-16
notable Trial sites expanded: 28 -> 41 locations 2026-05-09
notable Trial sites expanded: 24 -> 28 locations 2026-05-02
notable Trial sites expanded: 19 -> 24 locations 2026-04-24
notable Trial sites expanded: 14 -> 19 locations 2026-04-17
notable Trial sites expanded: 10 -> 13 locations 2026-04-03
Trial Details
NCT Number NCT07318558
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Ovarian Neoplasms, Ovarian Cancer
Enrollment 900 participants
Start Date 2026-02-16
Primary Completion 2033-02-25 (estimated)
Study Completion 2033-02-25 (estimated)
Updated on ClinicalTrials.gov 2026-08-14